IO Biotech, Inc. Material Event - What Happened

Hey everyone, let's break down some recent news from IO Biotech, Inc. in a way that makes sense, without all the confusing finance talk. Think of this as me explaining it to you over a cup of coffee.

---

1. What happened? (The actual event, in plain English)

So, IO Biotech, a company that's trying to develop new medicines, especially for cancer, just announced that they received a warning from Nasdaq, the stock exchange where their shares are traded. The warning is because their stock price has been trading below $1.00 per share for too long, which violates Nasdaq's rules for companies to stay listed.

2. When did it happen?

This news came out on December 17, 2025, when IO Biotech received the official notice.

3. Why did it happen? (The backstory)

IO Biotech is a "biotech" company, which means they're in the business of creating new drugs and treatments, often for serious diseases like cancer. Developing these drugs is a long, expensive, and risky process. They have to go through many stages of testing, called "clinical trials," to prove their drugs are safe and actually work.

Like many companies, IO Biotech's stock is traded on a major exchange, Nasdaq. Nasdaq has rules that companies must follow to keep their shares listed. One of these rules is that a company's stock price generally needs to stay above $1.00 per share. Unfortunately, IO Biotech's stock has been closing below this $1.00 mark for 30 consecutive trading days.

This event happened because their stock price dropped and stayed below the $1.00 threshold required by Nasdaq for continued listing.

4. Why does this matter? (The "So What?")

This is a big deal because it means IO Biotech is now at risk of having its shares removed from the Nasdaq stock exchange, which is called 'delisting.' While there's no immediate impact on trading, if they can't get their stock price back up, it could make it much harder for investors to buy and sell their shares, and it could hurt the company's reputation and ability to raise money in the future.

It affects the company's future plans, how quickly they might get new drugs to patients, and their overall financial health.

5. Who is affected?

• The Company (IO Biotech): They now have to figure out a way to boost their stock price to avoid delisting. This adds pressure and uncertainty.
• Employees: While not directly mentioned, a delisting could impact company morale and future prospects, which can indirectly affect employees.
• Patients: This news doesn't directly impact drug development, but financial instability could eventually affect their ability to fund trials.
• Investors/Shareholders: Anyone who owns stock in IO Biotech will definitely feel this. The stock price often reacts strongly to news like this, and the risk of delisting can make the stock less attractive, potentially leading to further price drops and reduced liquidity (how easily you can sell your shares).
• Partners: Any other companies working with IO Biotech might view this as a sign of financial instability, potentially impacting future collaborations.

6. What happens next? (Immediate and future implications)

Immediately, we can expect IO Biotech to work on strategies to increase its stock price. They have 180 calendar days, until June 16, 2026, to fix this problem. To regain compliance, their stock's closing bid price needs to be $1.00 or higher for at least 10 consecutive trading days.

Looking ahead, this could mean if they don't meet the deadline, they might be able to get an extension of another 180 days, but only if they meet other Nasdaq requirements and apply to transfer their listing to a different Nasdaq market (the Nasdaq Capital Market). If they can't regain compliance or get an extension, Nasdaq could issue a delisting notice, meaning their shares would no longer trade on Nasdaq. The company would then have the right to appeal, but it's a serious situation that could lead to their stock trading on a less prominent 'over-the-counter' market, which is generally less liquid and transparent.

7. What should investors/traders know? (Practical takeaways)

If you own IO Biotech stock, or are thinking about buying it, here's what to keep in mind:

• Volatility: Biotech stocks, especially those with drugs in clinical trials, can be very volatile. News like this can cause big swings in the stock price.
• Delisting Risk: The primary concern here is the potential delisting from Nasdaq. This can significantly impact the stock's liquidity and investor interest.
• The $1.00 Threshold: Keep a close eye on whether the stock can consistently trade above $1.00 in the coming months.
• Look at the Bigger Picture: While this news is important, consider how it fits into IO Biotech's overall strategy. Do they have other promising drugs in their pipeline? What's their cash situation like now? This notice is a symptom, not necessarily the root cause of the low stock price.
• Do Your Homework: Don't just react to headlines. Try to understand the details of the announcement and what it means for the company's long-term prospects. Watch for further announcements from the company about their next steps to regain compliance.

Disclaimer: This isn't financial advice! It's just an explanation of what happened. Always do your own research or talk to a financial advisor before making any investment decisions.